Skip to content

Author: Yann Godfrin

ENCALS 2026 – European Network to Cure ALS

By Yann Godfrin

Madrid, Spain – 24-26 June 2026 “SEALS”: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating Efficacy And Safety Of NX210c In Amyotrophic Lateral Sclerosis (ALS) Patients – Preliminary Results Presented by Dr Emilien Bernard, Hospices Civils de Lyon, Coordinating Investigator of SEALS study, during TRICALS Satellite at the ENCALS meeting: insights in recent and upcoming … Continued

SEALS Second DSMB Positive Review

By Yann Godfrin

📢Second DSMB review completed: Confirmation of a satisfactory safety and tolerability profile for NX210c Axoltis Pharma is pleased to announce that the Data Safety Monitoring Board (DSMB) has completed its second safety review of a cohort of the first 50 patients of the SEALS study and confirmed a good safety profile of NX210c. SEALS is a multicenter, … Continued

Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate

By Yann Godfrin

2 December, 2025 Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments. The funding, which includes new and historic investors, will enable the company to pursue the development of NX210c, its … Continued